[PREVENAR 13®, A PNEUMOCOCCAL CONJUGATE VACCINE FOR THE PREVENTION OF PNEUMOCOCCAL INFECTONS IN ADULTS AT RISK].
Pneumococcal infections remain a major public health issue in aging people. The recent publication of the CAPITA trial evaluating the efficacy of 13-valent pneumococcal conjugate vaccine (PCV13, Prevenar 13®) in elderly subjects has brought several countries including Belgium to modify their vaccinal recommendations. These new developments have motivated us to write this brief review about the burden of pneumococcal disease, the mechanism of action of conjugate vaccines, the clinical efficacy of PCV13 with a special emphasis on CAPITA data. The questions of herd protection and serotype substitution are also introduced as well as a summary of the more recent guidelines.
M
M
Moutschen
D000328:Adult; D006801:Humans; D022242:Pneumococcal Vaccines / Q000494:pharmacology*; D018074:Vaccines, Conjugate / Q000494:pharmacology*
C538862:13-valent pneumococcal vaccine; D022242:Pneumococcal Vaccines; D018074:Vaccines, Conjugate